5.95
Verve Therapeutics Inc stock is traded at $5.95, with a volume of 1.87M.
It is down -11.33% in the last 24 hours and down -25.44% over the past month.
Verve Therapeutics Inc clinical-stage company developing a new class of genetic medicines for cardiovascular disease, or CVD, with the potential to transform treatment from chronic therapies to single-course gene editing medicines. The current paradigm of chronic care is fragile requiring rigorous patient adherence, extensive healthcare infrastructure, and regular healthcare access, and leaves many patients without adequate care. Its pipelines are PCSK9, ANGPTL3, and LPA. The group has one reportable segment relating to the research and development of gene-editing medicines. The segment derives its current revenues from research and development collaborations.
See More
Previous Close:
$6.71
Open:
$6.6
24h Volume:
1.87M
Relative Volume:
1.22
Market Cap:
$528.33M
Revenue:
$20.65M
Net Income/Loss:
$-192.65M
P/E Ratio:
-2.2973
EPS:
-2.59
Net Cash Flow:
$-134.39M
1W Performance:
-3.57%
1M Performance:
-25.44%
6M Performance:
+6.06%
1Y Performance:
-60.23%
Verve Therapeutics Inc Stock (VERV) Company Profile
Name
Verve Therapeutics Inc
Sector
Industry
Phone
(978) 501-3026
Address
201 BROOKLINE AVENUE, BOSTON
Compare VERV with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
VERV
Verve Therapeutics Inc
|
5.95 | 528.33M | 20.65M | -192.65M | -134.39M | -2.59 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
500.01 | 128.40B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
744.83 | 81.43B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
571.00 | 34.69B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
233.07 | 30.17B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beone Medicines Ltd Adr
|
242.66 | 26.02B | 3.32B | -860.46M | -1.04B | -8.32 |
Verve Therapeutics Inc Stock (VERV) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Apr-08-24 | Initiated | H.C. Wainwright | Buy |
Apr-13-23 | Initiated | Canaccord Genuity | Buy |
Feb-01-23 | Initiated | Cantor Fitzgerald | Neutral |
Dec-15-22 | Initiated | Goldman | Sell |
Oct-06-22 | Initiated | Credit Suisse | Neutral |
Aug-25-22 | Upgrade | Stifel | Hold → Buy |
Jun-17-22 | Initiated | BMO Capital Markets | Outperform |
Feb-18-22 | Initiated | RBC Capital Mkts | Outperform |
Sep-24-21 | Initiated | Stifel | Hold |
Jul-12-21 | Initiated | Guggenheim | Buy |
Jul-12-21 | Initiated | JP Morgan | Neutral |
Jul-12-21 | Initiated | Jefferies | Buy |
Jul-12-21 | Initiated | William Blair | Outperform |
View All
Verve Therapeutics Inc Stock (VERV) Latest News
Verve Therapeutics, Inc. (NASDAQ:VERV) Shares Acquired by Rhumbline Advisers - Defense World
IFP Advisors Inc Boosts Holdings in Verve Therapeutics, Inc. (NASDAQ:VERV) - Defense World
(VERV) Technical Data - Stock Traders Daily
Verve Therapeutics (NASDAQ:VERV) Shares Gap Down After Analyst Downgrade - Defense World
Verve Therapeutics price target lowered to $15 from $17 at RBC Capital - TipRanks
RBC Cuts Price Target on Verve Therapeutics to $15 From $17, Keeps Outperform, Speculative Risk - Marketscreener.com
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Marketscreener.com
How Verve Therapeutics Is Attracting Talent: New Equity Compensation Package Details - StockTitan
Verve Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Verve Therapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 28, 2024VERV - ACCESS Newswire
Analysts Set Expectations for VERV Q1 Earnings - Defense World
Verve Therapeutics, Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky Before October 28, 2024 to Discuss Your RightsVERV - ACCESS Newswire
HC Wainwright Forecasts Strong Price Appreciation for Verve Therapeutics (NASDAQ:VERV) Stock - Defense World
Investors who lost money on Verve Therapeutics, Inc.(VERV) should contact Levi & Korsinsky about pending Class ActionVERV - ACCESS Newswire
Verve Therapeutics (VERV) Reports Q4 Loss, Tops Revenue Estimates - MSN
H.C. Wainwright lifts VERVE Therapeutics price target to $15 By Investing.com - Investing.com Canada
Promising Progress and Strategic Partnerships Position Verve Therapeutics as a Compelling Buy Opportunity - TipRanks
Verve Can Shrug Off Vertex Loss But Lilly Opt-In Is Crucial - News & Insights
Verve TherapeuticsKey Data Catalysts, Major Share Price Volatility In Play In Q2 - Seeking Alpha
Buy Rating for Verve Therapeutics: Promising Program Progress and Strong Financial Position - TipRanks
Verve Therapeutics: Buy Rating Backed by Promising VERVE-102 Program and Strategic Catalysts - TipRanks
VERV LAWSUIT ALERT: Levi & Korsinsky Notifies Verve Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ACCESS Newswire
Verve Therapeutics Full Year 2024 Earnings: Beats Expectations - Yahoo Finance
Verve Therapeutics Reports 2024 Financial Results and Pipeline Progress - TipRanks
Verve Therapeutics: Q4 Earnings Snapshot - Houston Chronicle
Verve Therapeutics earnings beat by $0.10, revenue topped estimates - Investing.com Canada
Verve Therapeutics, Inc. (VERV) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings - ACCESS Newswire
Verve Therapeutics reports Q4 EPS (58c), consensus (67c) - TipRanks
Vertex ends gene editing research pact with Verve - BioPharma Dive
Verve Therapeutics, Inc. SEC 10-K Report - TradingView
Verve Therapeutics: Q4 Earnings Snapshot -February 27, 2025 at 07:33 am EST - Marketscreener.com
Verve Therapeutics Announces Pipeline Progress and Reports Fourth Quarter and Full Year 2024 Financial Results - GlobeNewswire
Can Verve's Gene Editing Trials Deliver? Key PCSK9 Data Coming in 2025 With $524M War Chest - StockTitan
VERV STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Verve Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Shareholders of Verve Therapeutics, Inc. Should Contact Levi & Korsinsky Before October 28, 2024 to Discuss Your RightsVERV - ACCESS Newswire
VERV SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Verve Therapeutics, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
How To Trade (VERV) - Stock Traders Daily
William Blair Reaffirms Outperform Rating for Verve Therapeutics (NASDAQ:VERV) - Defense World
Verve Therapeutics (VERV) Projected to Post Quarterly Earnings on Tuesday - Defense World
VERV INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Verve Therapeutics, Inc. Investors Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Levi & Korsinsky Reminds Verve Therapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 28, 2024VERV - ACCESS Newswire
Shareholders that Lost Money on Verve Therapeutics, Inc. (VERV) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - ACCESS Newswire
Promising Outlook for Verve Therapeutics: Buy Rating Backed by Innovative Treatments and Strategic Partnerships - TipRanks
Optimistic Outlook for Verve Therapeutics Amid Promising Developments and Strategic Partnerships - TipRanks
VERV SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Verve Therapeutics, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Class Action Filed Against Verve Therapeutics, Inc. (VERV) Seeking Recovery for InvestorsContact Levi & Korsinsky - ACCESS Newswire
Investors Who Lost Money on Verve Therapeutics, Inc. (VERV) Should Contact Levi & Korsinsky About Pending Class ActionVERV - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Verve Therapeutics, Inc. (VERV) Investigation - ACCESS Newswire
Verve Therapeutics (VERV) Expected to Announce Quarterly Earnings on Tuesday - MarketBeat
Verve Therapeutics (NASDAQ:VERV) Trading 10.4% HigherShould You Buy? - MarketBeat
Verve Therapeutics (NASDAQ:VERV) Trading Down 4.9%Time to Sell? - MarketBeat
Verve Therapeutics Inc (VERV)’s stock decline to 7.98 per share - US Post News
Verve Therapeutics Inc Stock (VERV) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):